Volume 24, Issue 1 359840 pp. 27-32
Article
Open Access

Expression of MAGE-A12 in Oral Squamous Cell Carcinoma

Nur Mollaoglu

Corresponding Author

Nur Mollaoglu

Department of Oral and Maxillofacial Surgery, Friedrich- Alexander University of Erlangen/Nuremberg, Glückstrasse 11, 91054, Erlangen, Germany

Department of Oral and Maxillofacial Surgery, Gazi University, School of Dentistry, Emek 8.Cadde, 82.sokak, No:4, 06510, Ankara, Turkey

Search for more papers by this author
Eleftherios Vairaktaris

Eleftherios Vairaktaris

Department of Oral and Maxillofacial Surgery, University of Athens Medical School, Attikon Hospital, Rimini 1, GR 12462, Greece

Search for more papers by this author
Emeka Nkenke

Emeka Nkenke

Department of Oral and Maxillofacial Surgery, Friedrich- Alexander University of Erlangen/Nuremberg, Glückstrasse 11, 91054, Erlangen, Germany

Search for more papers by this author
Friedrich W. Neukam

Friedrich W. Neukam

Department of Oral and Maxillofacial Surgery, Friedrich- Alexander University of Erlangen/Nuremberg, Glückstrasse 11, 91054, Erlangen, Germany

Search for more papers by this author
Jutta Ries

Jutta Ries

Department of Oral and Maxillofacial Surgery, Friedrich- Alexander University of Erlangen/Nuremberg, Glückstrasse 11, 91054, Erlangen, Germany

Search for more papers by this author
First published: 21 November 2007
Citations: 18

Abstract

Melanoma associated-A antigens (MAGE-A) are silent in normal tissues except testis. However, they are activated in a variety of different tumors. Thus, their expression is highly specific to cancer cells. Reverse transcription-nested polymerase chain reaction (RT-nPCR) is a highly sensitive technique that has been used successfully for the detection ofMAGE genes in tissue samples. The aim of the study is to analyze the expression rate of MAGE-A12 in oral squamous cell carcinoma (OSCC) using a high sensitive RT-nPCR. Total of 57 tissue samples obtained from patients with OSCC and 20 normal oral mucosal (NOM) probes of otherwise healthy volunteers were included to this study. No expression of MAGE-A12 was observed in the non-neoplastic NOM tissues. MAGE-A12 was expressed in 49.1% of the investigated tumor samples. The correlation between malignant lesion and MAGE-A12 detection was significant (p < 0.001). It is concluded that results of this study may indicate MAGE-A12 as a useful additional diagnostic marker especially for the early detection of OSCC distinguishing neoplastic transformation and detection of occult and/or rare disseminated cancer cells. In addition, MAGE-A12 expression in OSCC may also determine a new immunotherapeutic target and might be warranted to develop vaccine for OSCC.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.